secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sonoma Pharmaceuticals, Inc. (SNOA)
CIK:        0001367083
Form:       8-K
Filed at:   2023-07-14T23:59:59+00:00
Accession:  0001683168-23-004933
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sonoma Pharmaceuticals appoints Controller and sets new interim CFO consulting terms
--------------------------------------------------------------------------------

- John Dal Poggetto appointed Controller effective July 17, 2023; annual salary $100,000, bonus up to 20%, option grant for 5,000 shares vesting over three years.
- New consulting agreement with Jerome Dvonch Consulting, LLC at $20,000/month, effective August 15, 2023, with Dvonch continuing as interim CFO.
- Dvonch's vested equity awards extended by one extra month per month of continued service, capped by current plan provisions.
- Dal Poggetto will work part-time, reporting to interim CFO Dvonch; role is at-will with standard benefits and 3 weeks vacation.
- No changes to other executive officers or board composition disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367083/000168316823004933/0001683168-23-004933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367083/000168316823004933/sonoma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-004933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer